ALLHAT-LLT Trial Summary: Pravastatin in Moderate HLD

allhat llt trial

2002 ALLHAT-LLT Pravastatin vs Usual Care in Moderately Hypercholesterolemic, Hypertensive Patients Multicenter, randomized, nonblinded trial M Objective: To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholes- terolemic, hypertensive participants with at least 1 additional CHD risk factor. Inclusion criteria: Ambulatory persons, aged 55 years or 10,355 older, with low-density lipoprotein cholesterol (LDL-C) of patients 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) triglycerides lower than 350 mg/dL Pravastatin (n=5170) VS Usual Care (n=5185) PRIMARY OUTCOME 631 All-cause mortality (no. of deaths) RR, 0.99; 95% CI, 0.89-1.11; P = 0.88 641 SECONDARY OUTCOME 380 Coronary heart disease (no. of events) RR, 0.91; 95% CI, 0.79-1.04; P = 0.16 421 209 Incidence of stroke (no. of events) RR, 0.91; 95% CI, 0.75-1.09; P = 0.31 231 Conclusion: Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C. ALLHAT group. JAMA. 2002;288(23):2998-3007